Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas
- 30 November 2010
- journal article
- research article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 177 (5), 2191-2204
- https://doi.org/10.2353/ajpath.2010.100217
Abstract
No abstract availableFunding Information
- Smoking Research Foundation
- Foundation for Development of Community
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 51 references indexed in Scilit:
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cellsBritish Journal of Cancer, 2009
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation studyNature Medicine, 2008
- Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences of the United States of America, 2008
- Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth FactorMolecular Cancer Research, 2008
- Integrin β6 Mediates Phospholipid and Collectin Homeostasis by Activation of Latent TGF-β1American Journal of Respiratory Cell and Molecular Biology, 2007
- P-cadherin expression in breast cancer: a reviewBreast Cancer Research, 2007
- Cyclooxygenases, prostanoids, and tumor progressionCancer and Metastasis Reviews, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arraysOncogene, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004